Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1

Next Previous
Trial Profile

10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Decitabine (Primary) ; Antithymocyte globulin; Fludarabine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use

Most Recent Events

  • 06 Apr 2021 Results assessing safety and efficacy of 10-day decitabine, fludarabine and 2 Gray TBI prior to allogeneic hematopoietic cell transplantation in poor risk acute myeloid leukemia patients, published in the Bone Marrow Transplantation.
  • 18 Mar 2020 Status changed from active, no longer recruiting to completed.
  • 03 May 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Oct 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top